Goldman Sachs analyst Corinne Jenkins raised the price target on Intra-Cellular Therapies (NASDAQ: ITCI) to $79.00 (from $74.00) while maintaining ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Analyst PT Change

Form 10-Q Intra-Cellular Therapies For: Sep 30October 30, 2024 7:54 AM Form 8-K Intra-Cellular Therapies For: Oct 30October 30, 2024 7:45 AM Intra-Cellular Therapies (ITCI) Misses Q3 EPS by 7c ; Offers GuidanceOctober 30, 2024 7:32 AM Intra-Cellular Therapies Reports Third Quarter 2024 Financial Results, Provides Corporate Update and Raises 2024 Caplyta Sales GuidanceOctober 30, 2024 7:30 AM